• Je něco špatně v tomto záznamu ?

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

B. Michelsen, M. Østergaard, MJ. Nissen, A. Ciurea, B. Möller, LM. Ørnbjerg, J. Zavada, B. Glintborg, A. MacDonald, K. Laas, D. Nordström, B. Gudbjornsson, F. Iannone, P. Hellmand, TK. Kvien, AM. Rodrigues, C. Codreanu, Z. Rotar, I. Castrejón...

. 2023 ; 33 (-) : 100706. [pub] 20230804

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015224

This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021-April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

Aberdeen Centre for Arthritis and Musculoskeletal Health University of Aberdeen UK

Amsterdam Rheumatology and Immunology Center Amsterdam the Netherlands

Center for Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania

Center for Treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Centre for Rheumatology Research Landspitali University Hospital Reykjavik Iceland

Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Rigshospitalet Glostrup Denmark

DANBIO and Copenhagen Center for Arthritis Research Center for Rheumatology and Spine Diseases Centre for Head and Orthopaedics Rigshospitalet Glostrup Denmark

Department of Clinical Medicine Aarhus University Aarhus Denmark

Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

Department of Clinical Sciences Lund Rheumatology Skåne University Hospital Lund University Lund Sweden

Department of Internal Medicine Dermatology and Psychiatry Universidad de la Laguna La Laguna Spain

Department of Medicine Helsinki University and Helsinki University Hospital Helsinki Finland

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Rheumatology Aarhus University Hospital Aarhus Denmark

Department of Rheumatology and Clinical Immunology Amsterdam University Medical Center Amsterdam the Netherlands

Department of Rheumatology and Clinical Immunology and Department of Experimental Immunology Amsterdam UMC University of Amsterdam Amsterdam Institute for Infection and Immunity Amsterdam the Netherlands

Department of Rheumatology and Immunology Inselspital University Hospital Bern Switzerland

Department of Rheumatology East Tallinn Central Hospital Tallinn Estonia

Department of Rheumatology Geneva University Hospital Geneva Switzerland

Department of Rheumatology Hospital Garcia de Orta Almada Portugal

Department of Rheumatology Hospital General Universitario Gregorio Marañón Madrid Spain

Department of Rheumatology University Hospital Zurich University of Zurich Zurich Switzerland

Department of Rheumatology University Medical Centre Ljubljana Ljubljana Slovenia

Departments of Medicine and Rheumatology Helsinki University Hospital Helsinki Finland

EpiDoC Unit Nova Medical School Lisbon Portugal

Faculty of Medicine Complutense University of Madrid Spain

Faculty of Medicine Universitiy of Ljubljana Ljubljana Slovenia

Faculty of Medicine University of Iceland Reykjavik Iceland

Institute of Rheumatology Prague Czech Republic

Instituto Medicina Molecular Faculdade de Medicina da Universidade de Lisboa Portugal

National Institute for Health Development Tallinn Estonia

NHS Grampian Scotland UK

Research Unit Sørlandet Hospital Kristiansand Norway

Reuma pt Sociedade Portuguesa de Reumatologia Lisbon Portugal

Rheumatology Service Hospital Universitario de Canarias La Laguna Spain

Rheumatology Unit DETO University of Bari Italy

Rheumatology Unit Hospital dos Lusíadas Lisbon Portugal

Rheumatology Unit University of Modena and Reggio Emilia Modena Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015224
003      
CZ-PrNML
005      
20231020093636.0
007      
ta
008      
231010s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lanepe.2023.100706 $2 doi
035    __
$a (PubMed)37601339
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Michelsen, Brigitte $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $u Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $u Research Unit, Sørlandet Hospital, Kristiansand, Norway
245    10
$a Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe / $c B. Michelsen, M. Østergaard, MJ. Nissen, A. Ciurea, B. Möller, LM. Ørnbjerg, J. Zavada, B. Glintborg, A. MacDonald, K. Laas, D. Nordström, B. Gudbjornsson, F. Iannone, P. Hellmand, TK. Kvien, AM. Rodrigues, C. Codreanu, Z. Rotar, I. Castrejón Fernández, JK. Wallman, J. Vencovsky, AG. Loft, M. Heddle, S. Vorobjov, AM. Hokkanen, G. Gröndal, M. Sebastiani, M. van de Sande, EK. Kristianslund, MJ. Santos, C. Mogosan, M. Tomsic, F. Díaz-González, D. Di Giuseppe, ML. Hetland
520    9_
$a This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021-April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Nissen, Michael John $u Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland
700    1_
$a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
700    1_
$a Möller, Burkhard $u Department of Rheumatology and Immunology, Inselspital - University Hospital Bern, Switzerland
700    1_
$a Ørnbjerg, Lykke Midtbøll $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
700    1_
$a Zavada, Jakub $u Institute of Rheumatology, Prague, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Glintborg, Bente $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $u DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
700    1_
$a MacDonald, Alan $u NHS Grampian, Scotland, UK
700    1_
$a Laas, Karin $u Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia
700    1_
$a Nordström, Dan $u Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland
700    1_
$a Gudbjornsson, Bjorn $u Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland
700    1_
$a Iannone, Florenzo $u Rheumatology Unit, DETO, University of Bari, Italy
700    1_
$a Hellmand, Pasoon $u Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, the Netherlands
700    1_
$a Kvien, Tore Kristian $u Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Rodrigues, Ana Maria $u Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal $u EpiDoC Unit, Nova Medical School, Lisbon, Portugal $u Rheumatology Unit, Hospital dos Lusíadas, Lisbon, Portugal
700    1_
$a Codreanu, Catalin $u Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, Universitiy of Ljubljana, Ljubljana, Slovenia
700    1_
$a Castrejón Fernández, Isabel $u Department of Rheumatology, Hospital General, Universitario Gregorio Marañón, Madrid, Spain $u Faculty of Medicine, Complutense University of Madrid, Spain
700    1_
$a Wallman, Johan Karlsson $u Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark $u Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
700    1_
$a Heddle, Maureen $u Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, UK
700    1_
$a Vorobjov, Sigrid $u National Institute for Health Development, Tallinn, Estonia
700    1_
$a Hokkanen, Anna-Mari $u Department of Medicine, Helsinki University and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Gröndal, Gerdur $u Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland
700    1_
$a Sebastiani, Marco $u Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy
700    1_
$a van de Sande, Marleen $u Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection & Immunity, Amsterdam, the Netherlands $u Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, the Netherlands
700    1_
$a Kristianslund, Eirik Klami $u Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Santos, Maria José $u Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal $u Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Portugal
700    1_
$a Mogosan, Corina $u Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Tomsic, Matija $u Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Medicine, Universitiy of Ljubljana, Ljubljana, Slovenia
700    1_
$a Díaz-González, Federico $u Department of Internal Medicine, Dermatology and Psychiatry, Universidad de la Laguna, La Laguna, Spain $u Rheumatology Service, Hospital Universitario de Canarias, La Laguna, Spain
700    1_
$a Di Giuseppe, Daniela $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
773    0_
$w MED00208007 $t The Lancet regional health. Europe $x 2666-7762 $g Roč. 33, č. - (2023), s. 100706
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37601339 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093629 $b ABA008
999    __
$a ok $b bmc $g 1997052 $s 1201586
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 33 $c - $d 100706 $e 20230804 $i 2666-7762 $m The Lancet regional health. Europe $n Lancet Reg Health Eur $x MED00208007
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace